AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3065929
Drug: Combined intramuscular
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intramuscular ampicillin and chloramphenicol (AMC)
Trial: 24430534
Drug: rilpivirine 25
RxNorm normalized name: rilpivirine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rilpivirine 25 mg once daily
Trial: 21150563
Drug: efavirenz 600
RxNorm normalized name: efavirenz 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: efavirenz 600 mg once daily
Trial: 22621465
Drug: New methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New methadone formulation
Trial: 22621465
Drug: Previous reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous reference formulation of methadone
Trial: 18717675
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 308-nm excimer laser phototherapy and topical hydrocortisone 17-butyrate cream
Trial: 11844898
Drug: Cafergot (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cafergot (1 mg ergotamine tartrate with 100 mg caffeine)
Trial: 11844898
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of eletriptan
Trial: 7588662
Drug: Intravenous maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous maintenance anaesthesia (alfentanil infusion 1-1.5 micrograms kg‐1 min‐1, midazolam injections 2.5-5 mg h‐1)
Trial: 3510384
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone (125 mg)
Trial: 12815771
Drug: Intravenous anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous anaesthesia
Trial: 7248984
Drug: Postmastectomy chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postmastectomy chemotherapy for 2 years
Trial: 16160710
Drug: 600 mg/day
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/day mifepristone for 8 days
Trial: 8713566
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group cC (10 not-AT-treated BP patients)
Trial: 27529839
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of ranibizumab (IVR) monotherapy
Trial: 19490053
Drug: Rufinamide 1600
RxNorm normalized name: Rufinamide
DrugBank: Rufinamide (DB06201)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rufinamide 1600 mg twice daily
Trial: 15221244
Drug: P. niruri
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P. niruri (450 mg capsules, td)
Trial: 3503108
Drug: Orally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered haloperidol
Trial: 3503108
Drug: Topical medications
RxNorm normalized name: Procto-Med Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical medications in glaucomatous patients
Trial: 26233764
Drug: Numerical skills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Numerical skills training program (twice a week for 2 months, 30 minutes per session)
Trial: 20467418
Drug: Rosiglitazone (ROSI)
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (ROSI) 8 mg daily
Trial: 18297434
Drug: Oral EGD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral EGD
Trial: 16554952
Drug: Calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium and vitamin D supplementation (800 IU daily)
Trial: 12888186
Drug: Omega-3 PUFAs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 PUFAs (6.6 g/day)
Trial: 14576756
Drug: Oral daily
RxNorm normalized name: Summer's Eve Sheer Floral Daily Cloths
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral daily supplementation with 0.5 mg cyanocobalamin, 0.8 mg folic acid and 3 mg vitamin B6 for 4 months
Trial: 10526245
Drug: TRH (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRH (200 microg, intravenously administered)
Trial: 8913433
Drug: Oral ftorafur
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ftorafur (370 mg/m2) and leucovorin (20 mg/m2)
Trial: 1895471
Drug: Continuous 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous 2.0 mg/h morphine infusion
Trial: 1895471
Drug: Continuous 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous 0.5 to 2 mg/h morphine infusion
Trial: 1895471
Drug: No morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No morphine infusion (control group)
Trial: 30790163
Drug: Intraperitoneal instillation
RxNorm normalized name: Taurolidine 20 mg/mL solution for intraperitoneal instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal instillation of 40 ml bupivacaine 0.25%
Trial: 26908302
Drug: Fentanyl iontophoretic
RxNorm normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl iontophoretic transdermal system (ITS) 40 µg/dose
Trial: 26908302
Drug: Morphine intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine intravenous patient-controlled analgesia (PCA) 1 mg/dose
Trial: 23529273
Drug: Post-dialysis dosing
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-dialysis dosing of cinacalcet (group AD) administered 3 times/week by dialysis staff.
Trial: 23529273
Drug: Daily home
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily home administration of cinacalcet (group D).
Trial: 23529273
Drug: Post-dialysis dosing
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-dialysis dosing of cinacalcet (group AD) in patients with less severe SHPT.
Trial: 23529273
Drug: Daily home
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily home administration of cinacalcet (group D) in patients with less severe SHPT.
Trial: 17340186
Drug: Multidimensional Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidimensional Treatment Foster Care Program for Preschoolers (MTFC-P)
Trial: 16287602
Drug: Purified mistletoe
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified mistletoe lectin (ML)
Trial: 16287602
Drug: Mistletoe plant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mistletoe plant extract IQ depleted from ML
Trial: 9804681
Drug: Topically applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied emulsion of an analgesic ammonium solution
Trial: 2695549
Drug: Calcium (Ca)
DrugBank: Calcium sulfate (DB15533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (Ca) supplementation 1.5 g daily for 12 weeks
Trial: 2695549
Drug: Calcium (Ca)
DrugBank: Calcium sulfate (DB15533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (Ca) supplementation 1 g daily for 8 weeks
Trial: 321087
Drug: Levamisole 150
RxNorm normalized name: levamisole 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole 150 mg/day for three consecutive days every fortnight (study 1 and first half of study 2)
Trial: 31677995
Drug: Traditional method
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional method of vacuum assisted wound closure for 8 weeks; dressing changed 3 times weekly, at 125 mmHg, mode of 2 min off and 5 min on.
Trial: 29462456
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 2700 mg/day for 6 months
Trial: 26289436
Drug: Leucine at
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucine at 0.45 kcal/min (total 9.9 g, 40.5 kcal)
Trial: 26289436
Drug: Leucine at
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucine at 0.15 kcal/min (total 3.3 g, 13.5 kcal)
Trial: 19047026
Drug: Oral hypoglycemics
RxNorm normalized name: ORAL HYPOGLYCEMIC AGENTS,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hypoglycemics
Trial: 12767415
Drug: amoxicillin/clavulanate
RxNorm normalized name: AMOXICILLIN/CLAVULANATE
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amoxicillin/clavulanate
Trial: 8995350
Drug: Dios (Daflon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dios (Daflon 500 mg)
Trial: 8127216
Drug: Mycobacterium w
RxNorm normalized name: Mycobacterium W Vaccine
DrugBank: Mycobacterium w. Vaccine (DB15798)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mycobacterium w vaccine (initial dose)
Trial: 8127216
Drug: Mycobacterium w
RxNorm normalized name: Mycobacterium W Vaccine
DrugBank: Mycobacterium w. Vaccine (DB15798)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mycobacterium w vaccine (booster dose)
Trial: 8127216
Drug: Placebo (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (initial dose)
Trial: 8127216
Drug: Placebo (booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (booster dose)
Trial: 3306131
Drug: Sandwich chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandwich chemotherapy (administered between surgery and postoperative irradiation)
Trial: 3306131
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy with CCNU and vincristine
Trial: 3306131
Drug: Sandwich chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandwich chemotherapy (as administered)
Trial: 3306131
Drug: Reduced radiotherapy
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced radiotherapy doses to the supratentorial area and to the spine in low risk patients
Trial: 2397975
Drug: Pulsed electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pulsed electrical field treatment administered over 36 weeks
Trial: 4922754
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 15 mg daily
Trial: 21164355
Drug: hApoA-I overexpression
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hApoA-I overexpression via intraportal/vector administration
Trial: 21164355
Drug: hApoA-I overexpression
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hApoA-I overexpression via intramuscular/vector administration
Trial: 19111806
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy, chemotherapy, or a combination
Trial: 17910225
Drug: Adhesive patch
RxNorm normalized name: ADHESIVE PATCH, MEDICATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adhesive patch applied to Class II cavities
Trial: 17910225
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (fillings without patch application)
Trial: 12027046
Drug: D-fenfluramine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-fenfluramine (30 mg p.o.)
Trial: 8917239
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of lidocaine/prilocaine (EMLA) cream
Trial: 6355269
Drug: C.B.S. tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C.B.S. tablets (1 four times daily)
Trial: 6355269
Drug: C.B.S. liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C.B.S. liquid (5 ml four times daily)
Trial: 6355269
Drug: C.B.S. tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C.B.S. tablets and liquid
Trial: 22014267
Drug: Gel containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel containing niosomes loaded with semi-purified fraction containing gallic acid from T. chebula galls (SN)
Trial: 22014267
Drug: Gel containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel containing niosomes loaded with semi-purified fraction containing gallic acid from T. chebula galls (SE)
Trial: 22014267
Drug: Gel containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel containing unloaded fraction (SS)
Trial: 22014267
Drug: Gel containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel containing gallic acid loaded in non-elastic niosomes (GN)
Trial: 22014267
Drug: Gel containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel containing gallic acid loaded in elastic niosomes (GE)
Trial: 22014267
Drug: Gel containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel containing niosomes loaded with semi-purified fraction containing gallic acid from T. chebula galls (SN and SE)
Trial: 11000320
Drug: Bioadhesive fluoride
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioadhesive fluoride tablets (0.5 mg F) used for 5 days
Trial: 11000320
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no fluoride supplements) for 5 days
Trial: 1395766
Drug: Intravenous dipyridamole
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous dipyridamole (up to 0.84 mg/kg in 10 min)
Trial: 1395766
Drug: Oral dipyridamole
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dipyridamole (300 mg of pulverized tablets)
Trial: 2082492
Drug: Intravenous dipyridamole
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous dipyridamole
Trial: 3901172
Drug: Sucralfate (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (300 mg daily)
Trial: 3901172
Drug: Cimetidine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (600 mg daily)
Trial: 29665829
Drug: HeLP-her program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HeLP-her program (one group session, monthly SMS text messages, one phone coaching session, and a program manual)
Trial: 22721642
Drug: LSM+miglitol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LSM+miglitol (50 mg × 3)
Trial: 18504332
Drug: Survey on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Survey on knowledge about ACS symptoms and treatment
Trial: 9223837
Drug: Dronabinol 2.5
RxNorm normalized name: dronabinol 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dronabinol 2.5 mg twice daily (90%) or 2.5 mg once daily (10%)
Trial: 3526773
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ampicillin, mecillinam and metronidazole (group I)
Trial: 27909310
Drug: Conventional treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatments (historical control)
Trial: 24610862
Drug: Mirabegron 25
RxNorm normalized name: mirabegron 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron 25 mg once-daily
Trial: 25092441
Drug: Mirabegron 50
RxNorm normalized name: mirabegron 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron 50 mg once-daily
Trial: 23850394
Drug: Mirabegron (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron (both doses)
Trial: 18822498
Drug: Vaccine against
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine against Haemophilus influenzae type b administered simultaneously with diphtheria-tetanus-whole cell pertussis and inactivated polio vaccines (Imovax Polio)
Trial: 18822498
Drug: Vaccine against
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine against Haemophilus influenzae type b
Trial: 16912120
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate (TE) 25, 50, 125, 300, or 600 mg weekly for 5 months
Trial: 16912120
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate (TE) 125, 300, and 600 mg
Trial: 12522515
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 or 400 mg/d
Trial: 12522515
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 to 400 mg/d
Trial: 16681880
Drug: Celecoxib 400
RxNorm normalized name: celecoxib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 400 mg/d
Trial: 2527130
Drug: Human lente
RxNorm normalized name: INSULIN HUMAN LENTE 100 UNIT/ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human lente insulin
Trial: 29059273
Drug: Tasquinimod (0.25-1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tasquinimod (0.25-1.0 mg/day orally)
Trial: 23945520
Drug: 0.5 cc
RxNorm normalized name: SureComfort Pen 30g, 0.5 cc, 5/16 inches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 cc mDHACM
Trial: 23945520
Drug: 1.25 cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 cc mDHACM
Trial: 23945520
Drug: Control (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (1.25 cc saline)
Trial: 17892885
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of EX/RP and CMI (EX/RP&CMI)
Trial: 14622688
Drug: Caffeine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (10 mg x kg(‐1) body weight)
Trial: 8460916
Drug: Enoxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxacin (400 mg orally every 12 h)
Trial: 28018112
Drug: Capsaicin infusion
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsaicin infusion
Trial: 25580060
Drug: roxithromycin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxithromycin (150 mg/day for 6 months)
Trial: 19111278
Drug: d‐amphetamine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐amphetamine (20 mg)
Trial: 18831930
Drug: Inhaled thiamphenicol
RxNorm normalized name: thiamphenicol
DrugBank: Thiamphenicol (DB08621)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled thiamphenicol associated with acetylcysteine (250 mg: 1/2 vial in the morning and 1/2 vial in the evening) for 5 days (Group A)
Trial: 18831930
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution twice daily for 5 days (Group B)
Trial: 15838660
Drug: Schedule A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schedule A: Docetaxel 60 mg/m² over 1 hour followed by Topotecan 0.85 mg/m² continuous infusion over 72 hours
Trial: 15838660
Drug: Schedule B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schedule B: Topotecan 0.85 mg/m² continuous infusion over 72 hours followed by Docetaxel 60 mg/m² over 1 hour
Trial: 10517908
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg oral diltiazem
Trial: 10517908
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily diltiazem
Trial: 10517908
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily diltiazem
Trial: 10517908
Drug: 0.1% bethanechol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% bethanechol gel
Trial: 7563935
Drug: Non-G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-G-CSF
Trial: 1891681
Drug: Intranasal budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intranasal budesonide aerosol (400 micrograms once daily)
Trial: 1891681
Drug: Budesonide dry
RxNorm normalized name: budesonide Dry Powder Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide dry powder (400 micrograms once daily)
Trial: 6337323
Drug: Refractoriness to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refractoriness to random-donor platelet infusions at transplantation
Trial: 30745097
Drug: NIT+IPC (NO3‐‐rich
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIT+IPC (NO3‐‐rich gel ingested 90min prior to testing)